[Results of clinical trials with the cation exchange preparation campanyl in the therapy and metaphylaxis of calcium-containing urinary calculi (author's transl)].
The efficacy of the cation exchange preparation Campanyl (T1286) was tested in the treatment and metaphylaxis of calcium-containing urinary calculi. For this purpose, in vitro experiments, animal exeriments, orienting clinical studies in 79 patients, and a long term clinical trial in 42 patients over 12 months were undertaken; 22 of the latter patients are also still being treated with the cation exchange preparation, the observation period for 15 patients being 3 1/2 years and 2 1/2 years for 7 patients. As a result of these studies a lowering of the medium calcium excretion and a reduction of calculus discharge by more than half was achieved in the patients being treated with the cation exchanger, without restriction of calcium in the diet. There was not yet seen litholysis. Serious side effects or an influence on the serum electrolytes was not recorded with Campanyl (T1286).
D002118:Calcium / Q000378:metabolism*; D002266:Carboxymethylcellulose Sodium / Q000627:therapeutic use; D002411:Cation Exchange Resins / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007475:Ion Exchange Resins / Q000627:therapeutic use*; D008297:Male; D011145:Polyvinyls / Q000627:therapeutic use*; D013012:Sorbitol / Q000627:therapeutic use; D014545:Urinary Calculi / Q000188:drug therapy* / Q000378:metabolism
D002411:Cation Exchange Resins; D004338:Drug Combinations; D007475:Ion Exchange Resins; D011145:Polyvinyls; D013012:Sorbitol; C015050:campanyl; D002266:Carboxymethylcellulose Sodium; D002118:Calcium
Ergebnisse klinischer Prüfungen des Kationenaustauscherpräparates Campanyl in der Therapie und Metaphylaxe calciumhaltiger Harnsteine.